NCT04539795已完成1 期
A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event
研究概览
简要总结
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18 years) with COVID-19 respiratory disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female
- •Age ≥18 years
- •Proven SARS-Cov-2 infection (confirmed by PCR from a nasopharyngeal or lower respiratory tract sample)
- •A score of Grade 3 to 5 on the WHO 9-point Ordinal Scale
- •Male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period.
- •Female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met:
- •Not a woman of childbearing potential OR A woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - Capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (ICF) and within this protocol.
排除标准
- •Patients who have previously had a score of 6 or 7 on the WHO 9-point Ordinal Scale
- •Patients who require support with invasive mechanical ventilation at the time of inclusion, or expected to be required within 24 hours of randomization
- •Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) >2 × the upper limit of normal (ULN) OR Total Bilirubin > ULN. In patients with a documented history of Gilbert's Syndrome AND baseline total bilirubin elevation consistent with an exacerbation of Gilbert's Syndrome (i.e. no other cause of total bilirubin elevation), subjects may enroll if total bilirubin is < 5x ULN.
- •Diagnosis of liver cirrhosis, esophageal varices, ascites or hepatic encephalopathy
- •Chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis
- •Significant renal disease or infection (as determined by the Investigator) including stage 4 chronic kidney disease or estimated glomerular filtration rate <60mL/min
- •Absolute neutrophil count ≤ 1000/µL at screening
- •Myocardial infarction, transient ischemic attack or stroke within 3 months prior to the first dose
- •Current unstable angina or congestive heart failure (New York Heart Association III/IV)
- •Screening 12-lead EKG with a measurable QTc interval according to Fridericia correction (QTcF) >450 ms
- •Anticipated transfer to another hospital that is not the study center within 24 hours
- •Allergy to study medication or excipients
- •Inability to swallow tablets
- •Other documented comorbidities or laboratory abnormalities that in the opinion of the Investigator could affect the outcome of the study assessments, participant safety, or ability of the participant to comply with the requirements of the protocol
- •Any patient whose interests are not best served by study participation, as determined by the Investigator
- •Excluded Prior/Concomitant Therapy
- •Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic index (eg, warfarin, phenytoin) is prohibited unless therapeutic monitoring available for duration of alvelestat dosing
- •Medicines that are potent CYP3A4 inhibitors including (but are not limited to) clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, verapamil and potent inducers including but not limited to phenobarbital, phenytoin and rifampicin, will be exclusionary
- •Requirement for medications substantially reliant on OATP1B1 for metabolism where discontinuation during study drug administration is not possible or where fluctuations in levels are considered clinically important (as per investigator judgement) and cannot be clinically monitored (e.g., statins, valsartan, olmesartan, enalapril, repaglinide)
- •Excluded Prior/Concurrent Clinical Study Experience
- •Participation in any clinical investigation using investigational treatments within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initial dosing (or longer if required by local regulations) is prohibited. Use of remdesivir (Veklury) under the conditions of the authorization for emergency use in the US, and per manufacturer's instructions, is permitted.
研究组 & 干预措施
Alvelestat oral tablet - dose 3
Active Comparator
MPH966
干预措施: Alvelestat (Drug)
Placebo oral tablet
Placebo Comparator
placebo
干预措施: Placebo (Drug)
Alvelestat oral tablet - dose 1
Active Comparator
MPH966
干预措施: Alvelestat (Drug)
Alvelestat oral tablet - dose 2
Active Comparator
MPH966
干预措施: Alvelestat (Drug)
结局指标
主要结局
Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event
时间窗: to day 60
Safety Outcome Assessment
次要结局
- Mortality Rate(to Day 90)
- Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of D-dimer(Randomization through Day 10 or hospital discharge, whichever was shorter.)
- Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of NETosis(Randomization through Day 10 or hospital discharge, whichever was shorter.)
- Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of Inflammation(Randomization through Day 10 or hospital discharge, whichever was shorter.)
- Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of Desmosine(Randomization through Day 10 or hospital discharge, whichever was shorter.)
研究者
James Michael Wells
Associate Professor
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 CapsulesHyperammonemiaNCT06178718TenNor Therapeutics (Suzhou) Limited58
撤回
2 期
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)Human Immunodeficiency VirusHIVNCT05115838Merck Sharp & Dohme LLC
尚未招募
1 期
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With SchizophreniaSchizophreniaNCT05964790Jiangsu Hansoh Pharmaceutical Co., Ltd.112
招募中
2 期
A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia2024-518929-15-00Centessa Pharmaceuticals UK Limited96
已完成
1 期
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With HyperammonemiaHyperammonemiaNCT06135675TenNor Therapeutics (Suzhou) Limited36